Dravet Syndrome Treatment Market Exhibits Higher Growth Prospects during 2019-2027
Dravet Syndrome Treatment Dravet syndrome (DS), also known as polymorphic epilepsy and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic brain dysfunction (epileptic encephalopathy). It usually starts in the first year of life and lasts the rest of one's life. Children with Dravet Syndrome Treatment Market experience a variety of seizures, including myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously known as partial seizures), and status epilepticus. Increasing R&D activities for the development of novel drugs for Dravet syndrome, and subsequent approval in key regions such as North America and Europe, are expected to drive growth in the Global Dravet Syndrome Treatment Market in the near future. Epygenix Therapeutics, Inc., a biopharmaceutical company, received orphan drug designation from the US Food and Drug Administration (FDA) in 2017 for its EP